{"id":"https://openalex.org/W4362492971","doi":"https://doi.org/10.1158/1535-7163.c.6536361","title":"Data from Biomarker Signatures Correlate with Clinical Outcome in Refractory Metastatic Colorectal Cancer Patients Receiving Bevacizumab and Everolimus","display_name":"Data from Biomarker Signatures Correlate with Clinical Outcome in Refractory Metastatic Colorectal Cancer Patients Receiving Bevacizumab and Everolimus","publication_year":2023,"publication_date":"2023-04-03","ids":{"openalex":"https://openalex.org/W4362492971","doi":"https://doi.org/10.1158/1535-7163.c.6536361"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.c.6536361","doi":"https://doi.org/10.1158/1535-7163.c.6536361","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1535-7163.c.6536361","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"http://dx.doi.org/10.1158/1535-7163.c.6536361","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5037380551","display_name":"Yingmiao Liu","orcid":"https://orcid.org/0000-0003-3516-5844","observed_orcids":["https://orcid.org/0000-0003-3516-5844"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yingmiao Liu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062010101","display_name":"Mark D. Starr","orcid":"https://orcid.org/0009-0003-9664-6235","observed_orcids":["https://orcid.org/0009-0003-9664-6235"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mark D. Starr","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103918869","display_name":"John C. Brady","orcid":"https://orcid.org/0009-0004-7982-1211","observed_orcids":["https://orcid.org/0009-0004-7982-1211"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"John C. Brady","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070264002","display_name":"Christel N. Rushing","orcid":"https://orcid.org/0000-0001-7453-2120","observed_orcids":["https://orcid.org/0000-0001-7453-2120"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Christel Rushing","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043601003","display_name":"Anuradha Bulusu","orcid":"https://orcid.org/0000-0002-0302-5751","observed_orcids":["https://orcid.org/0000-0002-0302-5751"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anuradha Bulusu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084337375","display_name":"Herbert Pang","orcid":"https://orcid.org/0000-0002-7896-6716","observed_orcids":["https://orcid.org/0000-0002-7896-6716"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Herbert Pang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069465431","display_name":"Wanda Honeycutt","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Wanda Honeycutt","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003099045","display_name":"Anthony Amara","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anthony Amara","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012856380","display_name":"Ivy P. Altomare","orcid":"https://orcid.org/0000-0002-1222-885X","observed_orcids":["https://orcid.org/0000-0002-1222-885X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ivy Altomare","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000347168","display_name":"Hope Elizabeth Uronis","orcid":"https://orcid.org/0009-0000-1565-1939","observed_orcids":["https://orcid.org/0009-0000-1565-1939"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hope E. Uronis","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046311492","display_name":"Herbert I. Hurwitz","orcid":"https://orcid.org/0000-0003-3242-9197","observed_orcids":["https://orcid.org/0000-0003-3242-9197"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Herbert I. Hurwitz","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5044586794","display_name":"Andrew B. Nixon","orcid":"https://orcid.org/0000-0003-3971-2964","observed_orcids":["https://orcid.org/0000-0003-3971-2964"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Andrew B. Nixon","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11355","display_name":"Inflammatory Biomarkers in Disease Prognosis","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.996999979019165},{"id":"https://openalex.org/keywords/everolimus","display_name":"everolimus","score":1.0},{"id":"https://openalex.org/keywords/plasma-biomarkers","display_name":"plasma biomarkers","score":0.7289999723434448},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.8460000157356262},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8960000276565552},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":1.0},{"id":"https://openalex.org/keywords/c-reactive-protein","display_name":"C-reactive protein","score":0.8100000023841858},{"id":"https://openalex.org/keywords/growth-related-oncogene-alpha","display_name":"growth-related oncogene alpha","score":0.7129999995231628},{"id":"https://openalex.org/keywords/igfbp-1","display_name":"IGFBP-1","score":0.7509999871253967},{"id":"https://openalex.org/keywords/igfbp-2","display_name":"IGFBP-2","score":0.871999979019165},{"id":"https://openalex.org/keywords/igfbp-3","display_name":"IGFBP-3","score":0.9990000128746033},{"id":"https://openalex.org/keywords/tgf-beta-receptor-iii","display_name":"TGF-beta receptor III","score":0.6959999799728394},{"id":"https://openalex.org/keywords/tissue-factor","display_name":"tissue factor","score":0.7649999856948853},{"id":"https://openalex.org/keywords/icam-1","display_name":"ICAM-1","score":0.9760000109672546},{"id":"https://openalex.org/keywords/thbs2","display_name":"thrombospondin-2","score":0.9039999842643738},{"id":"https://openalex.org/keywords/inflammation","display_name":"inflammation","score":0.6079999804496765},{"id":"https://openalex.org/keywords/igf-signaling","display_name":"IGF signaling","score":0.996999979019165},{"id":"https://openalex.org/keywords/mtor","display_name":"mTOR","score":0.6480000019073486},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.5680000185966492}],"concepts":[{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.8306313157081604},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7715069055557251},{"id":"https://openalex.org/C2779699572","wikidata":"https://www.wikidata.org/wiki/Q421052","display_name":"Everolimus","level":2,"score":0.7550292611122131},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6898194551467896},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.6607469916343689},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.6106890439987183},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5817029476165771},{"id":"https://openalex.org/C2781197716","wikidata":"https://www.wikidata.org/wiki/Q864574","display_name":"Biomarker","level":2,"score":0.5665303468704224},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.5035261511802673},{"id":"https://openalex.org/C50382708","wikidata":"https://www.wikidata.org/wiki/Q223218","display_name":"Proportional hazards model","level":2,"score":0.48477739095687866},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.42813044786453247},{"id":"https://openalex.org/C3019894029","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Overall survival","level":2,"score":0.2651088833808899},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.18207502365112305},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.1396811306476593},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1535-7163.c.6536361","doi":"https://doi.org/10.1158/1535-7163.c.6536361","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1535-7163.c.6536361","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/1535-7163.c.6536361","doi":"https://doi.org/10.1158/1535-7163.c.6536361","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1535-7163.c.6536361","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2113058482","https://openalex.org/W1985335252","https://openalex.org/W2077980958","https://openalex.org/W4200493332","https://openalex.org/W4361957679","https://openalex.org/W2186364980","https://openalex.org/W2795491662","https://openalex.org/W2142765731","https://openalex.org/W2608179723","https://openalex.org/W4311089005"],"abstract_inverted_index":{"Abstract":[0],"A":[1],"novel":[2],"combination":[3],"of":[4,43,90,113,143,197],"bevacizumab":[5,84,171],"and":[6,37,50,59,85,97,105,116,121,129,134,146,157,172,180,192],"everolimus":[7,86],"was":[8],"evaluated":[9],"in":[10,15,78,168],"refractory":[11],"colorectal":[12],"cancer":[13],"patients":[14,28],"a":[16],"phase":[17],"II":[18],"trial.":[19],"In":[20],"this":[21],"retrospective":[22],"analysis,":[23],"plasma":[24],"samples":[25],"from":[26],"49":[27],"were":[29,53,71,81,125,165],"tested":[30],"for":[31,127,140],"over":[32],"40":[33],"biomarkers":[34,164],"at":[35,48,152],"baseline":[36,49,138],"after":[38],"one":[39],"or":[40],"two":[41],"cycles":[42],"drug":[44],"administration.":[45],"Analyte":[46],"levels":[47,89],"change":[51],"on-treatment":[52,150],"correlated":[54,94,118,176],"with":[55,95,119,177,190],"progression-free":[56],"survival":[57,61],"(PFS)":[58],"overall":[60],"(OS)":[62],"using":[63,73],"univariate":[64],"Cox":[65,74],"proportional":[66],"hazard":[67],"modeling.":[68,75],"Multivariable":[69],"analyses":[70],"conducted":[72],"Significant":[76],"changes":[77,112],"multiple":[79,163],"markers":[80,92,175,184],"observed":[82],"following":[83],"treatment.":[87],"Baseline":[88],"six":[91],"significantly":[93,166],"PFS":[96,120,130,179],"OS,":[98],"including":[99],"CRP,":[100,144],"Gro-\u03b1,":[101,145],"IGFBP-1,":[102],"TF,":[103,147],"ICAM-1,":[104],"TSP-2":[106],"(P":[107,131],"<":[108],"0.05).":[109],"At":[110],"C2D1,":[111],"IGFBP-3,":[114,156],"TGF\u03b2-R3,":[115],"IGFBP-2":[117],"OS.":[122,181],"Prognostic":[123],"models":[124],"developed":[126],"OS":[128,141],"=":[132],"0.0002":[133],"0.004,":[135],"respectively).":[136],"The":[137],"model":[139,151],"consisted":[142],"while":[148],"the":[149],"C2D1":[153],"included":[154],"IGFBP-2,":[155],"TGF\u03b2-R3.":[158],"These":[159],"data":[160],"demonstrated":[161],"that":[162],"modulated":[167],"response":[169],"to":[170,187],"everolimus.":[173],"Several":[174],"both":[178],"Interestingly,":[182],"these":[183],"are":[185],"known":[186],"be":[188],"associated":[189],"inflammation":[191],"IGF":[193],"signaling,":[194],"key":[195],"modulators":[196],"mTOR":[198],"biology.":[199],"Mol":[200],"Cancer":[201],"Ther;":[202],"14(4);":[203],"1048\u201356.":[204],"\u00a92015":[205],"AACR.":[206]},"counts_by_year":[],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2023-04-05T00:00:00"}